New York, Jan 9, 2026, 15:11 EST — Regular session
- CRISPR Therapeutics shares fell about 4% in afternoon trade.
- A filing showed the company’s CFO exercised options and sold shares under a pre-set plan.
- Investors are looking to next week’s JPMorgan healthcare conference slot and mid-February earnings calendars.
CRISPR Therapeutics AG shares slid on Friday, bucking a firmer broader market, after a regulatory filing flagged a chief financial officer’s share sale under a pre-arranged trading plan. 1
The company’s CFO, Raju Prasad, exercised stock options for 29,700 common shares and sold 29,700 shares the same day at prices around $60, a Form 4 filed on Jan. 8 showed. The filing indicated the sales were made under a Rule 10b5-1 plan, a preset trading instruction meant to limit allegations of trading on inside information. 2
The timing matters because investors are heading into a dense stretch for biotech: management teams cycle through the J.P. Morgan Healthcare Conference, and attention snaps back to cash use and early sales trends for newer drugs. CRISPR Therapeutics is scheduled to present at the conference on Jan. 12 at 8:15 a.m. PST, according to its website. 3
CRISPR shares were down 4.3% at $54.00, after trading as low as $53.82 on the day. The stock’s 52-week range runs from $30.04 to $78.48, according to Yahoo Finance data. 4
Gene-editing peers were also weaker on the day, with Intellia Therapeutics, Beam Therapeutics and Editas Medicine all down, while partner Vertex Pharmaceuticals traded lower.
The next hard catalyst is earnings. Market calendars tracked by Nasdaq and Yahoo Finance point to a mid-February report, though the company has not confirmed a date; investors typically focus on any read-through on product revenue, spending and runway. 5
CRISPR’s valuation still leans heavily on CASGEVY, the CRISPR-based treatment approved in the U.S. in late 2023. In its most recent quarterly update, the company highlighted reimbursement progress and said partner Vertex expected a clearer line of sight to more than $100 million in total CASGEVY revenue in 2025, with growth expected in 2026. 6
But commercial rollouts in rare diseases can move in fits and starts. Patient identification, treatment-center capacity, reimbursement decisions and payer timelines can all delay revenue that looks “inevitable” on a slide deck. A risk for holders is that uptake stays lumpy into 2026, keeping pressure on cash burn and sentiment.
Traders will watch Monday’s J.P. Morgan conference remarks for any update on CASGEVY access and demand, then look for a firm earnings date and guidance markers as the next checkpoint. 7
